Design, synthesis, and biological evaluation of novel iso-flavones derivatives as H₃R antagonists

References

• Sadek B, Saad A, Sadeq A, et al. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behav Brain Res 2016;312:415–30.
   PubMed Web of Science ®Google Scholar
• Ellenbroek BA, Ghiabi B. The other side of the histamine H3 receptor. Trends Neurosci 2014;37:191–9.
   PubMed Web of Science ®Google Scholar
• Berlin M, Boyce CW, Ruiz Mde L. Histamine H3 receptor as a drug discovery target. J Med Chem 2011;54:26–53.
   PubMed Web of Science ®Google Scholar
• Vanhanen J, Kinnunen M, Nuutinen S, Panula P. Histamine H3 receptor antogonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs. Psychopharmacology 2015;232:1143–53.
   PubMed Web of Science ®Google Scholar
• Leurs R, Bakker RA, Timmerman H, de Esch IJ. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005;4:107–20.
   PubMed Web of Science ®Google Scholar
• Banuelos-Cabrera I, Cuéllar-Herrera M, Velasco AL, et al. Pharmacoresistant temporal lobe epilepsy modifies histamine turnover and H3 receptor function in the human hippocampus and temporal neocortex. Epilepsia 2016;57:e76–80.
   PubMed Web of Science ®Google Scholar
• Rouleau A, Ligneau X, Tardivel-Lacombe J, et al. Histamine H3-receptor-mediated [35S]GTPγ[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors. Br J Pharmacol 2002;135:383–92.
   PubMed Web of Science ®Google Scholar
• Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001;63:637–72.
   PubMed Web of Science ®Google Scholar
• Riddy DM, Cook AE, Diepenhorst NA, et al. Isoform-specific biased agonism of histamine H3 receptor agonists. Mol Pharmacol 2017;91:87–99.
   PubMed Web of Science ®Google Scholar
• Bordi F, Rivara S, Dallaturca E, et al. Dibasic biphenyl H3 receptor antagonists: steric tolerance for a lipophilic side chain. Eur J Med Chem 2012;48:214–30.
   PubMed Web of Science ®Google Scholar
• Wager TT, Pettersen BA, Schmidt AW, et al. Discovery of two clinical histamine H3 receptor antagonists: trans-N-ethyl-3-fluoro-3- [3-fluoro-4-(pyrrolidinylmethyl)phenyl] cyclobutanecarbox amide (PF-03654746) andtrans- 3 -fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl) phenyl]-N-(2-methylpropyl)cyc lobutanecarboxamide (PF-03654764). J Med Chem 2011;54:7602–20.
   PubMed Web of Science ®Google Scholar
• Delay-Goyet P, Blanchard V, Schussler N, et al. SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy. Alzheimers Dement 2016;2:267–80.
   Google Scholar
• Sadek B, Schwed JS, Subramanian D, et al. Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties. Eur J Med Chem 2014;77:269–79.
   PubMed Web of Science ®Google Scholar
• Pierson PD, Fettes A, Freichel C, et al. 5-Hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity. J Med Chem 2009; 52:3855–68.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Watanabe T, Kudo T, et al. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J Med Chem 2010;53:6445–56.
   PubMed Web of Science ®Google Scholar
• Hudkins RL, Raddatz R, Tao M, et al. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl) propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. J Med Chem 2011;54:4781–92.
   PubMed Web of Science ®Google Scholar
• Hagenow S, Stasiak A, Ramsay RR, Stark H. Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B. Sci Rep 2017;7:40541.
   PubMed Web of Science ®Google Scholar
• Provensi G, Costa A, Passani MB, Blandina P. Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse. Neuropharmacology 2016;109:139–47.
   PubMed Web of Science ®Google Scholar
• Patnaik R, Sharma A, Skaper SD, et al. Histamine H3 inverse agonist BF 2649 or antagonist with partial H4 agonist activity clobenpropit reduces amyloid beta peptide-induced brain pathology in Alzheimer’s disease. Mol Neurobiol 2018;55:312–21.
   PubMed Web of Science ®Google Scholar
• Iida T, Yoshikawa T, Karpati A, et al. JNJ10181457, a histamine H3 receptor inverse agonist, regulates in vivo microglial functions and improves depression-like behaviours in mice. Biochem Biophys Res Commun 2017;488:534–40.
   PubMed Web of Science ®Google Scholar
• Tao M, Aimone LD, Huang Z, et al. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H3 receptor antagonists with potent cognition enhancing activity. J Med Chem 2012;55:414–23.
   PubMed Web of Science ®Google Scholar
• Singh M, Kaur M, Silakari O. Flavones: an important scaffold for medicinal chemistry. Eur J Med Chem 2014; 84:206–39.
   PubMed Web of Science ®Google Scholar
• Feng B, Li X, Xia J, Wu S. Discovery of novel isoflavone derivatives as AChE/BuChE dual-targeted inhibitors: synthesis, biological evaluation and molecular modelling. J Enzyme Inhib Med Chem 2017; 32:968–77.
   PubMed Web of Science ®Google Scholar
• Carmela S, Stefania M, Gian LR. Anti-inflammatory effects of flavonoids in neurodegenerative disorders. Eur J Med Chem 2018;153:105–15.
   PubMed Web of Science ®Google Scholar
• Wen G, Liu Q, Hu H, et al. Design, synthesis, biological evaluation, and molecular docking of novel flavones as H3 R inhibitors. Chem Biol Drug Des 2017;90:580–9.
   PubMed Web of Science ®Google Scholar